Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival

Table 1 Demographic and Clinical Characteristics of ALS patients in different HbA1c status (N = 450)

HbA1c, %	<5.7	5.7–6.4	≥6.5	P-trend
Number	263	152	35
Age of onset, years	52.7(12.6)	57.0(11.2)	57.7(10.0)	<0.001
Age, years	53.1(15.3)	58.5(11.2)	59.4(9.8)	<0.001
Gender
Male, %	57.4	53.3	62.9	0.52
Female, %	42.6	46.7	37.1
Onset form
Upper limb, %	54.8	51.9	62.9	0.20
Lower limb, %	20.9	29.6	22.9
Bulbar, %	24.3	19.1	14.3
ALS disease duration, months	16.0(15.5)	17.7(16.9)	19.7(16.4)	0.33
ALS diagnostic delay, months	14.9(14.8)	16.2(15.9)	19.1(16.6)	0.29
Education, years	7.9(4.3)	7.6(4.5)	6.2(2.9)	0.28
ALSFRS-R total score	39.3(5.7)	38.6(6.1)	38.3(7.5)	0.35
Rate of disease progression	0.75(0.65)	0.78(0.65)	0.84(0.71)	0.79
FAB (N = 195)
<16 score, %	37.7	35.1	54.5	0.48
≥ 16 score, %	62.3	64.9	45.5
ACE-R (N = 195)
<75, %	38.0	40.7	33.3	0.86
≥ 75, %	62.0	59.3	66.7

Abbreviations: ALS amyotrophic lateral sclerosis, HbA1c Hemoglobin A1c, ALSFRS-R amyotrophic lateral sclerosis functional rating scale-revised, FAB frontal assessment battery, ACE-R Addenbrooke’s Cognitive Examination-revised

ISSN: 1750-1326